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OBJECTIVES This study was done to determine the effects of angiotensin-converting enzyme (ACE)
inhibition and other clinical factors on troponin release in non-ST-elevation acute coronary
syndrome (ACS).
BACKGROUND Troponin is now widely used as a marker of risk in ACS, but determinants of its release have
not been defined.
METHODS This was a prospective cohort study of 301 consecutive patients admitted with non–ST-
elevation ACS. Baseline clinical data were recorded, ACE gene polymorphism was deter-
mined and serial blood samples were obtained for troponin-I assay.
RESULTS Significant troponin-I release (.0.1 mg/l) was detected in 93 (31%) patients. Pretreatment
with ACE inhibitors, recorded in 53 patients (17.6%), independently reduced the odds of
troponin-I release (odds ratio 0.25; 95% confidence intervals 0.10 to 0.64) and was associated
with lower maximum troponin-I concentrations (median [interquartile range]) compared
with patients not pretreated with ACE inhibitors (0.44 mg/l [0.19 to 2.65 mg/l] vs. 4.18 mg/l
[0.91 to 12.41 mg/l], p 5 0.01). Pretreatment with aspirin, recorded in 173 patients (57.5%),
did not significantly reduce the odds of troponin-I release after adjustment but was associated
with lower maximum troponin-I concentrations compared with patients not pretreated with
aspirin (2.31 mg/l [0.72 to 8.02 mg/l] vs. 5.85 mg/l [1.19 to 12.79 mg/l], p 5 0.05). The ACE
genotyping (n 5 268) showed 81 patients (30%) DD homozygous and 77 (29%) II
homozygous. There was no association between ACE genotype and troponin release.
CONCLUSIONS We conclude that ACE inhibition reduces troponin release in non-ST-elevation ACS. This
is likely to be mediated by the beneficial effects of treatment on vascular reactivity and the
coagulation system. (J Am Coll Cardiol 2001;38:724–8) © 2001 by the American College
of Cardiology
Troponin release occurs in about a third of all patients with
unstable angina and is widely used for risk stratification,
being associated with a 20% rate of death and myocardial
infarction (MI) in the first six months compared with a 2%
rate in troponin-negative cases (1). It reflects ischemic
myocardial injury, probably caused by transient thrombotic
occlusion at the site of plaque rupture or thrombotic
embolization into the distal arterial bed (2). Thus, both
troponin release and prognosis in unstable angina are likely
to be determined, at least in part, by the thrombotic burden,
which in turn is influenced by factors affecting the degree of
plaque disruption and the coagulability of the blood (3,4).
Identification of these factors may have important implica-
tions for risk reduction in unstable angina, yet to date there
have been no studies in which determinants of troponin
release have been clearly documented.
The renin-angiotensin system is a potential determinant
of troponin release through its ability to regulate coronary
endothelial function and influence vascular reactivity, en-
dogenous thrombolytic activity and platelet activation (5–9).
This may have important clinical implications because the
renin-angiotensin system is amenable to therapeutic modi-
fication, and the benefits of angiotensin-converting enzyme
(ACE) inhibition for risk reduction in cardiovascular disease
have already been demonstrated (10). In the present study,
therefore, we have prospectively analyzed troponin-I con-
centrations in an unselected cohort of patients with non-
ST-elevation acute coronary syndromes (ACS) to determine
whether pretreatment with ACE inhibitors and the ACE
gene polymorphism influence troponin release.
METHODS
Patients. Consecutive patients with non–ST-elevation
ACS were recruited if they fulfilled criteria for Braunwald
From the *Departments of Cardiology, †Clinical Biochemistry and ‡Diabetes and
Metabolic Medicine, St. Bartholomew’s and the Royal London School of Medicine
and Dentistry, Queen Mary, University of London, London; §Department of
Cardiology, Newham Healthcare Trust, London; and the \MRC Epidemiology and
Medical Care Unit, Charterhouse Square, London, United Kingdom. Biochemical
assays were funded by Bayer Plc, Newbury, United Kingdom.
Manuscript received January 10, 2001; revised manuscript received May 8, 2001,
accepted May 22, 2001
Journal of the American College of Cardiology Vol. 38, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01426-7
class 3B unstable angina (11). Electrocardiographic (ECG)
changes (ST depression, T-wave inversion) were not re-
quired for inclusion, but patients who developed Q-waves
were excluded as were patients with MI in the previous 21
days. Other exclusion criteria included percutaneous coro-
nary intervention in the previous six months and cardiac
failure (New York Heart Association class III or IV). The
study protocol was approved by the East London and the
City Research Ethics Committee, and all patients gave
written informed consent.
Data collection. CLINICAL DATA. Baseline characteristics
including demographic, clinical and biochemical data as
well as details of the presenting ECG were collected
prospectively and stored electronically. Medication being
taken prior to admission was documented.
BLOOD SAMPLING AND BIOCHEMICAL ANALYSIS. In addi-
tion to samples taken for routine laboratory analysis accord-
ing to hospital protocols, samples were also taken on
admission (before antithrombotic therapy) for troponin-I
assay and ACE genotyping and at 12, 24 and 48 h after
admission for troponin-I assays only. Whole blood and,
after separation, serum samples were stored at 280°C for
analysis in batches. Troponin-I concentrations were mea-
sured using a one-step sandwich immunoassay with mag-
netic separation (Bayer Immuno 1 Analyzer, Bayer Plc,
Newbury, United Kingdom). The coefficient of variation
was 3.2% at 2.5 mg/l and 10% at 0.3 mg/l (manufacturer’s
data sheet). As recommended by the manufacturer, the
cutoff point used was 0.1 mg/l.
DETERMINATION OF ACE GENOTYPES. Genomic deoxyri-
bonucleic acid was extracted from 200 ml of whole blood
with a QIAmp (96 wells per plate) blood kit (QIAGEN,
Crawley, United Kingdom). The ACE genotype was deter-
mined as previously described (12) and recently modified
(13). Briefly, amplification by polymerase chain reaction
using previously described specific primers flanking the
polymorphic region in intron 16 of the ACE gene yielded a
480 bp amplicon (I allele) and/or a 191 bp amplicon (D
allele), which were analyzed on a 3% agarose gel. Because
there is preferential amplification of the D allele in het-
erozygotes, all ACE DD individuals were verified by ream-
plification with primers specific for the 287 deleted alu
repeat region as previously described (14).
Statistical analysis. Results for continuous variables are
presented as means and SD. Two sample t tests were used
to compare those with and without peak troponin concen-
trations .0.1 mg/l. Variables not normally distributed are
presented as medians and interquartile ranges and compared
using the Mann-Whitney U-test. Categorical variables are
presented as numbers and percentages and compared using
either the chi-square test or the Fisher exact test. Variables
significant (p # 0.05) on univariate analysis were selected
for testing in a stepwise multiple logistic regression model.
The criterion for entry at each stage was significance at the
5% level. We then looked at the effect of adding variables
insignificant on univariate analysis to test whether any of
these became important after adjustment. Results from the
logistic regression were expressed as the odds of having a
peak troponin-I . 0.1 mg/l relative to a reference category
for categorical variables and as the relative odds associated
with a 1 SD increase in continuous variables. The Pearson
x2 test was used to compare the ACE genotype in those
with and without peak troponin concentrations .0.1 mg/l.
RESULTS
A total of 304 patients were recruited, but troponin data
were unavailable in three patients because of insufficient
sample size and sample wastage. The remaining 301 pa-
tients comprised the study group in whom troponin posi-
tivity (.0.1 mg/l) was recorded in 93 patients (31%).
Univariate predictors of troponin positivity. In patients
who were troponin positive, pretreatment with ACE inhib-
itors and aspirin was recorded significantly less frequently
than in patients who were troponin negative (Table 1).
Troponin-positive patients were older but less likely to
report a previous history of ACS or coronary revasculariza-
tion. Admission blood concentrations of creatinine and
glucose were higher in troponin-positive patients, and
cholesterol showed a similar trend. Ischemic ECG changes
and peak creatine kinase concentrations were strongly asso-
ciated with troponin release.
Multivariate predictors of troponin positivity. Logistic
regression analysis showed that pretreatment with ACE
inhibitors independently reduced the odds of troponin
release by 75%. Troponin release was also less likely in those
who had previously presented with unstable angina, but
pretreatment with aspirin had no independent effect. Isch-
emic ECG changes, however, more than doubled the odds
of troponin release, which also increased by 70% for every 1
SD increase in admission serum glucose concentration, and
by 25% for every five-year increase in age (Table 2).
The magnitude of troponin release. Detectable troponin
release occurred in 98 (33%) of the 301 patients recruited.
Peak troponin concentrations in these patients were unre-
lated to many of the variables associated with troponin
positivity, including previous ACS and coronary revascular-
ization. Pretreatment with aspirin and ACE inhibitors,
however, was associated with a 61% (p 5 0.05) and 89%
(p 5 0.01) decrease in peak troponin concentrations, re-
spectively (Table 3).
The ACE gene polymorphism. The ACE genotype data
were available in 268 patients, of whom 81 (30%) were DD
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACS 5 acute coronary syndromes
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
MI 5 myocardial infarction
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homozygous, 77 (29%) II homozygous and 110 (41%) DI or
ID heterozygous. There was no association between tropo-
nin status and ACE gene polymorphism, the incidence of
troponin positivity being similar in all three genotypes
(Pearson x2 5 2.7981; p 5 0.247). This remained the case
after adjustment for all baseline variables, including pre-
treatment with ACE inhibitors (Table 4).
DISCUSSION
ACE inhibition and troponin release. This prospective
study of non–ST-elevation ACS has shown that troponin
release is influenced importantly by ACE inhibition, an
observation that has not previously been reported. Thus, in
patients pretreated with ACE inhibitors, the odds of tro-
ponin positivity were reduced by 65%, and maximum
troponin concentrations were almost 90% lower than in
patients not pretreated with ACE inhibitors. This cardio-
protective effect may account, at least in part, for the
benefits of these drugs in patients at high risk of cardiac
events reported by the Heart Outcomes Prevention Evalu-
ation (HOPE) study investigators (10). This hypothesis is
strengthened by the well-documented effects of ACE inhi-
bition on endothelial function and the coagulation system,
which provide potential mechanisms whereby pretreatment
might reduce myocardial injury. Thus, ACE inhibition
restores endothelium-dependent vasodilator responses in
patients with coronary artery disease (CAD), helping to
preserve coronary flow when luminal patency is threatened
by thrombosis (5). Moreover, ACE inhibition may also
modify the thrombotic burden by enhancing the endoge-
nous fibrinolytic system through reductions in endothelial
production of plasminogenactivator inhibitor-1 (6,7). Re-
ductions in platelet aggregability have also been reported
(8,9). The combination of improved coronary vasodilator
activity, enhanced endogenous fibrinolysis and reduced
platelet aggregability would provide an environment more
conducive to coronary patency during plaque events, readily
accounting for the beneficial effects that pretreatment with
ACE inhibitors had on troponin release in this study of
non-ST-elevation ACS.
The ACE genotype. Similar mechanisms have been pro-
posed to explain the protection against coronary events seen
Table 1. Baseline Characteristics According to Troponin Status
TnI < 0.1 mg/l*
(n 5 208)




Age 58.8 (10.9) 64.5 (10.6) ,0.0001
Male gender 150 (72.1) 75 (80.7) 0.12
Non-Caucasian 53 (25.5) 21 (22.6) 0.59
Diabetic 43 (20.7) 24 (25.8) 0.32
Hypertensive 94 (45.2) 41 (44.1) 0.86
Smoker 62 (29.8) 34 (36.6) 0.25
Family history 112 (53.9) 37 (39.8) 0.02
Cardiac history
Unstable angina 56 (26.9) 10 (10.8) 0.002
Myocardial infarction 89 (42.8) 27 (29.0) 0.02
Revascularization 46 (22.1) 10 (10.8) 0.02
Admission medication
Aspirin 128 (61.8) 45 (48.4) 0.03
Beta-blockers 58 (28.0) 17 (18.3) 0.07
ACE-inhibitors 46 (22.2) 7 (7.5) 0.002
Statins 38 (18.4) 12 (12.9) 0.24
Calcium channel blockers 77 (37.2) 35 (37.6) 0.94
Biochemistry
Cholesterol 5.61 (1.14) 5.85 (1.15) 0.09
Glucose 6.3 (5.7–7.6) 7 (6–11.7) 0.0007
Creatinine 102.3 (22.4) 108.7 (22.2) 0.02
ECG Characteristics
T-wave inversion 94 (45.2) 61 (65.6) 0.001
ST depression 42 (20.2) 47 (50.5) ,0.0001
*TnI # 0.1 mg/l 5 maximum troponin concentration # 0.1 mg/l.
Data are numbers (%) except for age, cholesterol, creatinine, urea and creatine
kinase peak, which are mean (SD), and glucose, which is median (interquartile range).
ACE 5 angiotensin-converting enzyme; ECG 5 electrocardiography; TnI 5
troponin-I.





T inversion 2.73 (1.45–5.17) 0.002
ST depression 2.44 (1.29–4.63) 0.006
Glucose* 1.70 (1.27–2.30) ,0.001
Age* 1.25 (1.08–1.45) 0.002
Unstable angina 0.36 (0.15–0.87) 0.02
ACE inhibitors 0.25 (0.10–0.64) 0.004
*Odds ratios are for a five-year increase in age and a 1 SD increase in glucose.
Odds ratios represent odds of maximum troponin-I concentrations being .0.1
mg/l.
ACE 5 angiotensin-converting enzyme.
Table 3. Maximum Troponin-I (mg/l) Concentrations




Aspirin 5.85 (1.19–12.79) 2.31 (0.72–8.02) 0.05
(n 5 49) (n 5 49)
ACE inhibitors 4.18 (0.91–12.41) 0.44 (0.19–2.65) 0.01
(n 5 91) (n 5 7)
Beta-blockers 4.07 (0.91–11.0) 2.12 (0.78–12.79) 0.48
(n 5 80) (n 5 18)
Smoker 4.95 (0.91–12.65) 2.17 (0.71–9.41) 0.21
(n 5 62) (n 5 36)
Family history 2.31 (0.72–8.02) 6.62 (1.92–12.65) 0.06
(n 5 59) (n 5 39)
Cardiac history
Unstable angina 3.95 (0.9–11.77) 3.08 (0.68–8.02) 0.57
(n 5 87) (n 5 11)
Myocardial infarction 3.76 (0.8–10.99) 4.30 (0.91–12.79) 0.94
(n 5 68) (n 5 30)
Revascularization 4.07 (0.86–11.47) 2.58 (0.85–6.23) 0.52
(n 5 88) (n 5 10)
Data are medians (interquartile range).
ACE 5 angiotensin-converting enzyme.




TnI # 0.1 mg/l (n 5 182) 60 (74.1) 69 (62.7) 53 (68.8)
TnI . 0.1 mg/l (n 5 86) 21 (25.9) 41 (37.3) 24 (31.2)
Data are numbers (%). Pearson x2 5 2.7981; p 5 0.247.
ACE 5 angiotensin-converting enzyme; TnI 5 troponin-I.
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in individuals homozygous for the insertion polymorphism
of the ACE gene in whom endogenous converting enzyme
activity is lower than in individuals homozygous for the
deletion polymorphism (15–17). However, this has not been
a consistent finding (14), and in the present study troponin
release was not influenced by ACE genotype. This may
reflect the rather modest 40% relative reduction in ACE
activity associated with the II polymorphism (15,16), which
is considerably less than the 90% reduction in ACE activity
produced by therapeutic doses of ACE inhibitors (16,18).
Aspirin and troponin release. Among patients pretreated
with aspirin, troponin positivity was less common, and peak
troponin levels were 60% lower than in patients not taking
aspirin. Although these are new findings, they require
cautious interpretation as a significant independent relation
between pretreatment with aspirin and troponin release did
not emerge from the multivariate analysis. Interestingly, in
the Thrombolysis In Myocardial Infarction trial risk score
for unstable angina/non–ST-elevation MI, use of aspirin in
the seven days prior to presentation was an independent
predictor of adverse prognosis (19). This remains unex-
plained and, in view of the demonstrable efficacy of aspirin
as a secondary preventative measure (20), counterintuitive.
Protection against troponin release would be a predictable
response to the antiplatelet effects of aspirin, reductions in
thrombosis helping to preserve coronary patency and reduce
distal embolization and myocardial injury during plaque
events. In this respect the effects of aspirin were analogous
to those demonstrated in our previous studies of ACS in
which pretreatment has been associated with less severe
modes of presentation (21,22).
Other factors influencing troponin release. The strong
independent effect of increasing age on troponin release is
likely to reflect age-related changes in vascular endothelial
function and thrombogenicity. Thus, advanced age has been
shown to impair endothelium-dependent coronary vasodi-
lation and is also associated with increases in circulating
fibrinogen and factor VII levels compared with younger
individuals (23–25). These changes in vascular reactivity
and thrombogenicity in the elderly would predispose to
exaggerated thrombotic responses to plaque events, increas-
ing the propensity to coronary occlusion and distal emboli-
zation, which are thought to account for ischemic myocar-
dial injury and troponin release in non-ST-segment/
elevation coronary syndromes. Changes in thrombogenicity
may also have contributed to the relation between glycemia
and troponin release in the present study, blood glucose
being an independent predictor of platelet-dependent
thrombosis in patients with CAD (26). Nevertheless, gly-
cemia—a well-recognized response to increased sympatho-
adrenal activation—is commonly taken to reflect the sever-
ity of ACS and, like ischemic ECG changes, therefore,
associations with troponin release may have been casual
rather than causal. The association between previous admis-
sions with unstable angina and troponin release may relate
to the protective effect of myocardial collateralization
(27,28) and preconditioning (29,30).
Study limitations. The study was not powered to detect
small differences in troponin status associated with ACE
gene polymorphisms, and the possibility of a type II error
cannot be ruled out. This contrasts with our observations
concerning drug use and troponin status where differences
were large and statistically significant despite the relatively
small sample size. Nevertheless, it remains possible that
with larger numbers an effect of statins would also have been
detected and that statin treatment may have contributed
more to the multivariate model.
Conclusions. This study has shown that pretreatment with
ACE inhibitors is associated with reductions in troponin
release in patients with non–ST-elevation ACS. Although
causality has not been proven in this study, the association
is likely to be mediated by the beneficial effects of treatment
on vascular reactivity and the coagulation system. Because
reductions in troponin release are associated with parallel
reductions in risk, our observations provide a plausible new
mechanism whereby ACE inhibition might contribute to
secondary prevention in patients with CAD.
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